Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

R Gutzmer; L Rivoltini; E Levchenko; A Testori; J Utikal; P A Ascierto; L Demidov; J J Grob; R Ridolfi; D Schadendorf; P Queirolo; A Santoro; C Loquai; B Dreno; A Hauschild; Erwin Schultz; T P Lesimple; N Vanhoutte; B Salaun; M Gillet; S Jarnjak; P M De Sousa Alves; J Louahed; V G Brichard; F F Lehmann

doi:10.1136/esmoopen-2016-000068

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

R Gutzmer, L Rivoltini, E Levchenko, A Testori, J Utikal, P A Ascierto, L Demidov, J J Grob, R Ridolfi, D Schadendorf, P Queirolo, A Santoro, C Loquai, B Dreno, A Hauschild, Erwin Schultz (Co-author), T P Lesimple, N Vanhoutte, B Salaun, M GilletS Jarnjak, P M De Sousa Alves, J Louahed, V G Brichard, F F Lehmann

Department of Dermatology

Research output: Contribution to journal › Original Article › peer-review

58 Citations (Web of Science)

Original language	English
Pages (from-to)	e000068
Journal	ESMO OPEN
Volume	1
Issue number	4
DOIs	https://doi.org/10.1136/esmoopen-2016-000068
Publication status	Published - 2016

Keywords

T-CELL RESPONSES
FUNCTIONAL-ANALYSIS
TUMOR-ANTIGEN
IPILIMUMAB
PEPTIDES
MAGE-A3
PROTEIN
IDENTIFICATION
IMMUNIZATION
VACCINATION

Access to Document

10.1136/esmoopen-2016-000068

Cite this

Gutzmer, R., Rivoltini, L., Levchenko, E., Testori, A., Utikal, J., Ascierto, P. A., Demidov, L., Grob, J. J., Ridolfi, R., Schadendorf, D., Queirolo, P., Santoro, A., Loquai, C., Dreno, B., Hauschild, A., Schultz, E., Lesimple, T. P., Vanhoutte, N., Salaun, B., ... Lehmann, F. F. (2016). Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO OPEN, 1(4), e000068. https://doi.org/10.1136/esmoopen-2016-000068

@article{130e87d2ff244b0998352c1dcf7e9309,

title = "Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.",

keywords = "T-CELL RESPONSES, FUNCTIONAL-ANALYSIS, TUMOR-ANTIGEN, IPILIMUMAB, PEPTIDES, MAGE-A3, PROTEIN, IDENTIFICATION, IMMUNIZATION, VACCINATION",

author = "R Gutzmer and L Rivoltini and E Levchenko and A Testori and J Utikal and Ascierto, {P A} and L Demidov and Grob, {J J} and R Ridolfi and D Schadendorf and P Queirolo and A Santoro and C Loquai and B Dreno and A Hauschild and Erwin Schultz and Lesimple, {T P} and N Vanhoutte and B Salaun and M Gillet and S Jarnjak and {De Sousa Alves}, {P M} and J Louahed and Brichard, {V G} and Lehmann, {F F}",

note = "Schultz: Department of Dermatology, Paracelsus Medical University, Klinikum Nuremberg, Nuremberg, Germany",

year = "2016",

doi = "10.1136/esmoopen-2016-000068",

language = "English",

volume = "1",

pages = "e000068",

journal = "ESMO OPEN",

issn = "2059-7029",

publisher = "Elsevier ",

number = "4",

}

Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, PA, Demidov, L, Grob, JJ, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, TP, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, PM, Louahed, J, Brichard, VG & Lehmann, FF 2016, 'Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.', ESMO OPEN, vol. 1, no. 4, pp. e000068. https://doi.org/10.1136/esmoopen-2016-000068

TY - JOUR

T1 - Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

AU - Gutzmer, R

AU - Rivoltini, L

AU - Levchenko, E

AU - Testori, A

AU - Utikal, J

AU - Ascierto, P A

AU - Demidov, L

AU - Grob, J J

AU - Ridolfi, R

AU - Schadendorf, D

AU - Queirolo, P

AU - Santoro, A

AU - Loquai, C

AU - Dreno, B

AU - Hauschild, A

AU - Schultz, Erwin

AU - Lesimple, T P

AU - Vanhoutte, N

AU - Salaun, B

AU - Gillet, M

AU - Jarnjak, S

AU - De Sousa Alves, P M

AU - Louahed, J

AU - Brichard, V G

AU - Lehmann, F F

N1 - Schultz: Department of Dermatology, Paracelsus Medical University, Klinikum Nuremberg, Nuremberg, Germany

PY - 2016

Y1 - 2016

KW - T-CELL RESPONSES

KW - FUNCTIONAL-ANALYSIS

KW - TUMOR-ANTIGEN

KW - IPILIMUMAB

KW - PEPTIDES

KW - MAGE-A3

KW - PROTEIN

KW - IDENTIFICATION

KW - IMMUNIZATION

KW - VACCINATION

U2 - 10.1136/esmoopen-2016-000068

DO - 10.1136/esmoopen-2016-000068

M3 - Original Article

C2 - 27843625

SN - 2059-7029

VL - 1

SP - e000068

JO - ESMO OPEN

JF - ESMO OPEN

IS - 4

ER -